Search TELA
TELA Bio, Inc.
Nasdaq · CIK 1561921
Last close1.14
Daily change-0.11 (-8.80%)
10 Years gain-91.46%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
TELA · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
54.0Momentum
78.2Acceleration
78.2Confidence
77.0Annual Revenue9
Quarterly Revenue29
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth21.3 / 25
Quality20.3 / 25
Capital Efficiency0.0 / 20
Balance Sheet9.7 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 0.7392 percentage points.
Operating leverageOperating margin improved by 5.641 percentage points.
Warnings
Heavy share dilution · HIGHDiluted share count increased 26.8349%.
Key Metrics
Revenue Growth TTM12.92%OK
Revenue CAGR 3Y24.68%OK
Gross Margin68.83%OK
Operating Margin-45.99%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-218.48%OK
Incremental Operating Margin 3Y0.68%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y26.83%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $80.28M | $54.34M | -$33.76M | -$28.22M | -$28.67M | 67.69% | -42.05% | -35.71% | -190.25% | 46.95M |
| 2025 FY Dec 31, 2024 | $69.30M | $46.49M | -$34.12M | -$41.60M | -$42.58M | 67.08% | -49.23% | -61.45% | -182.23% | 28.53M |
| 2025 FY Dec 31, 2023 | $58.45M | $40.11M | -$44.08M | -$40.86M | -$41.47M | 68.62% | -75.4% | -70.94% | -280.02% | 22.87M |
| 2024 FY Dec 31, 2022 | $41.42M | $27.04M | -$39.01M | -$40.75M | -$41.62M | 65.3% | -94.18% | -100.49% | -310.33% | 16.27M |
| 2023 FY Dec 31, 2021 | $29.46M | $18.81M | -$29.45M | -$30.43M | -$31.06M | 63.85% | -99.96% | -105.42% | -354.75% | 14.47M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $79.24M | sum latest 4 fiscal quarters Revenue | OK | 0001104659-26-094039, 0001104659-25-112476 |
| Revenue Growth TTM | 12.92% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001104659-26-094039, 0001104659-25-112476 |
| Revenue CAGR 3Y | 24.68% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-034507 |
| Revenue CAGR 5Y | 34.54% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-034507 |
| Gross Profit CAGR 3Y | 26.19% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-034507 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001104659-26-094039, 0001104659-25-112476 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 68.83% | Gross Profit / Revenue | OK | 0001104659-26-094039, 0001104659-25-112476 |
| Operating Margin | -45.99% | Operating Income / Revenue | OK | 0001104659-26-094039, 0001104659-25-112476 |
| ROIC | -218.48% | NOPAT / Average Invested Capital | OK | 0001104659-26-094039, 0001104659-25-112476 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001104659-26-094039 |
| Current Ratio | 2.99x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.54x | (Cash + Short-term Investments) / Total Debt | OK | 0001104659-26-094039 |
| Revenue per Diluted Share | $1.38 | Revenue / Diluted Shares | OK | 0001104659-26-094039, 0001104659-25-112476 |